United States — Food and Drug Administration & GenBioPro

United States — Food and Drug Administration: The United States — Food and Drug Administration's rule allowing mifepristone to be prescribed online and dispensed through the mail was temporarily halted by an appellate court, but later paused by the United States — Supreme Court of the United States. The agency is conducting a safety review of mifepristone.

GenBioPro: GenBioPro, a manufacturer of a generic version of mifepristone, also received temporary relief from Samuel Alito's order. The company appealed to the United States — Supreme Court of the United States, stating that the 5th Circuit's decision 'unleashed regulatory chaos' and threatened access to mifepristone nationwide.

United States — Food and Drug Administration: The United States — Food and Drug Administration's regulations allowing mail-order mifepristone were overruled by the United States — United States Court of Appeals for the Third Circuit, despite the agency's long-standing judgments on drug safety.

GenBioPro: GenBioPro, a generic Mifepristone manufacturer, stated that the court's decision ignores the United States — Food and Drug Administration's science and decades of safe use of the drug.

United States — Food and Drug Administration: The United States — Food and Drug Administration's regulations regarding mifepristone access were challenged, and the agency is conducting a safety review of the medication.

GenBioPro: GenBioPro, a manufacturer of a generic version of mifepristone, also filed an emergency appeal, contributing to the United States — Supreme Court of the United States's decision to restore access.